Porton Pharma Solutions and Aojin Life Sciences Announce Strategic Collaboration to Advance XDC Conjugate Drugs for Dual IND Filings in China and the U.S.
Recently, Porton Pharma Solutions Ltd. (“Porton”) announced a strategic partnership with Aojin Life Sciences (Yixing) Co., Ltd. (“Aojin Life Sciences”).
Porton will provide comprehensive CDMO services for Aojin in the CMC pharmaceutical research and GMP production of XDC conjugate drugs, …